Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan;5(1):25-40.
doi: 10.1177/1758834012458137.

The changing landscape in the treatment of metastatic castration-resistant prostate cancer

Joelle El-Amm  1 , Jeanny B Aragon-Ching
Affiliations

The changing landscape in the treatment of metastatic castration-resistant prostate cancer

Joelle El-Amm et al. Ther Adv Med Oncol. 2013 Jan.

Abstract

The past few years have brought increasing advances in the therapeutic management of metastatic castration-resistant prostate cancer with the approval of several agents, including vaccine therapy with sipuleucel-T, second-line chemotherapy with cabazitaxel, the bone-targeted pharmaceutical denosumab, and the novel antiandrogen therapy abiraterone acetate. There are ongoing developments with other agents in the pipeline such as MDV3100 and alpharadin that have shown promising results. This review describes the clinical trials that brought about the drug approvals of various agents and offers some insights regarding a rational approach to optimal treatment sequencing for these drugs since national guidelines are currently lacking.

Keywords: Androgen deprivation therapy; chemotherapy; metastatic castration-resistant prostate cancer; vaccine therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Dr Aragon-Ching has served on the Advisory Board of Janssen/Ortho-Biotech, Sanofi-Aventis, and Amgen and has served on the Speakers’ Bureau of Janssen/Ortho-Biotech and Sanofi- Aventis.

References

    1. Aragon-Ching J. (2011) Unravelling the role of denosumab in prostate cancer. Lancet 377: 785–786 - PubMed
    1. Aragon-Ching J., Dahut W. (2007) Chemotherapy in androgen-independent prostate cancer (AIPC): what’s next after taxane progression? Cancer Ther 5A: 151–160 - PMC - PubMed
    1. Aragon-Ching J., Ning Y., Chen C., Latham L., Guadagnini J., Gulley J., et al. (2009) Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest 27: 221–226 - PMC - PubMed
    1. Armstrong A., Garrett-Mayer E., Yang Y., de Wit R., Tannock I., Eisenberger M. (2007) A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 13: 6396–6403 - PubMed
    1. Armstrong A., George D. (2010) Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. Prostate Cancer Prostatic Dis 13: 108–116 - PubMed

LinkOut - more resources